Diabetes News and Research

Latest Diabetes News and Research

Ischemic stroke: an interview with Dr Gregory Ford

A stroke is a sudden interruption of blood flow to the brain which deprives the brain of oxygen and nutrients. Approximately two millions brain cells die each minute during a stroke. This can lead to brain damage, physical and mental disability and death.

1 Nov 2012

Study finds how effective healthcare can reduce toll from major diseases like stroke, cancer

Wide differences in death rates from disease still persist throughout England - but effective healthcare can help to reduce these inequalities, a new study has discovered.

1 Nov 2012

Benaroya Research Institute at Virginia Mason wins Grand Challenges Explorations grant

Benaroya Research Institute at Virginia Mason (BRI) announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation.

1 Nov 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Regular exercise does not impact amount of time women spend sitting

Women who exercise regularly spend as much time sitting as women who don't, according to a new Northwestern Medicine study.

1 Nov 2012

Affordable Medicines Facility improves access to anti-malarials

The Affordable Medicines Facility-malaria has resulted in significant improvements in the availability and price of quality-assured artemisinin-based combination therapies in seven African countries after 1 year, show study findings published in The Lancet.

31 Oct 2012

Gene variant predicts lymphoma treatment response

German researchers have identified a gene variant that significantly influences the outcome of methotrexate therapy for primary central nervous system lymphoma.

31 Oct 2012

Smoke-free laws lead to fewer heart attacks

A recent decline in the incidence of myocardial infarction in Olmsted County, Minnesota, USA, could be due to the implementation of smoke-free laws, researchers suggest.

31 Oct 2012

SSRIs should be prescribed with great caution to those attempting to get pregnant

Elevated risk of miscarriage, preterm birth, neonatal health complications and possible longer term neurobehavioral abnormalities, including autism, suggest that a class of antidepressants known as selective serotonin reuptake inhibitors (SSRI) should only be prescribed with great caution and with full counseling for women experiencing depression and attempting to get pregnant, say researchers at Beth Israel Deaconess Medical Center, Tufts Medical Center and MetroWest Medical Center.

31 Oct 2012

Cost of searching for fountain of youth exceeds cost for medications to treat chronic disease

The cost of searching for the fountain of youth has become increasingly expensive and now exceeds the cost for medications used to treat chronic disease, according to new research released today at the American Public Health Association's 140th Annual Meeting in San Francisco, Calif.

31 Oct 2012

SSRIs should be prescribed with great caution to those attempting to get pregnant

31 Oct 2012

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

A new analysis of the Women's Health Initiative (WHI) trials show that women who had metabolic syndrome before they started hormone therapy had a greatly increased risk of heart attack or dying of heart disease. Women who didn't have metabolic syndrome beforehand showed no increased risk.

31 Oct 2012

Oily fish consumption may reduce risk of stroke

Eating at least two servings of oily fish a week is moderately but significantly associated with a reduced risk of stroke, finds a study published on bmj.com today.

31 Oct 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Adolescent overweight and obesity may increase risk of all-cause ESRD

Being overweight and obese during adolescence appears related to an increased risk of all-cause treated end-stage renal disease (ESRD) during a 25-year period, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

30 Oct 2012

Study compares 'cardio-toxicity' of Toronto-area neighborhoods

Your chances of having a sudden cardiac arrest can depend on where you live, warned Dr. Paul Dorian today at the Canadian Cardiovascular Congress 2012 in Toronto, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Autoantibody aids identification of hyperexcitability disorders

Researchers have found that testing for a glycine receptor autoantibody aids the identification of a broad spectrum of autoimmune brainstem/spinal cord hyperexcitability disorders.

29 Oct 2012

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform.

29 Oct 2012

Diabetes News and Research

Latest Diabetes News and Research

Ischemic stroke: an interview with Dr Gregory Ford

Study finds how effective healthcare can reduce toll from major diseases like stroke, cancer

Benaroya Research Institute at Virginia Mason wins Grand Challenges Explorations grant

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Regular exercise does not impact amount of time women spend sitting

Affordable Medicines Facility improves access to anti-malarials

Gene variant predicts lymphoma treatment response

Smoke-free laws lead to fewer heart attacks

SSRIs should be prescribed with great caution to those attempting to get pregnant

Cost of searching for fountain of youth exceeds cost for medications to treat chronic disease

SSRIs should be prescribed with great caution to those attempting to get pregnant

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

Oily fish consumption may reduce risk of stroke

FDA accepts Sunovion’s two LATUDA sNDAs for review

Nabilone shows promise in treating diabetic neuropathy

Adolescent overweight and obesity may increase risk of all-cause ESRD

Study compares 'cardio-toxicity' of Toronto-area neighborhoods

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

Autoantibody aids identification of hyperexcitability disorders

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Genomics - Industry Focus eBook (2nd edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Diabetes News and Research

Latest Diabetes News and Research

Genomics - Industry Focus eBook (2nd edition) eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in